This is the French translation of the Yale Manual for Psilocybin-Assisted Therapy of Depression. Le Manuel de Yale pour le traitement thérapeutique de la dépression assisté par la psilocybine fournit aux chercheurs et aux thérapeutes des méthodes, une structure et des domaines à prendre en compte concernant l'utilisation de la thérapie assistée par les psych...
Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggests that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period. Aims: To learn the extent to which serotonergic antidepressants may diminish psilo...
Microdosing is the practice of regularly using very low doses of psychedelic drugs. Anecdotal reports suggest that it may enhance well-being, creativity and cognition. Here, we use data from a self-blinding microdose trial, a large (n=240) placebo-controlled citizen science trial of microdosing to investigate whether tolerance develops during microdosing. We...
The Yale Program for Psychedelic Science (YPPS) is testing the safety and efficacy of psilocybin, administered in conjunction with non-directive psychological support, as a treatment for certain neurological and psychiatric conditions. The study, HIC: 200020355 (Neural correlates of the effects of psilocybin in obsessive-compulsive disorder: A double-blind, ...
Background: Therapeutic administration of psychedelic drugs has shown significant potential in historical accounts and in recent clinical trials in the treatment of depression and other mood disorders. A recent randomized double-blind phase-IIb study demonstrated the safety and efficacy of COMP360, COMPASS Pathways’ proprietary synthetic formulation of psilo...
Background: The Relaxed Beliefs Under pSychedelics (REBUS) model proposes that serotonergic psychedelics decrease the precision weighting of neurobiologically-encoded beliefs, and offers a unified account of the acute and therapeutic action of psychedelics. Although REBUS has received some neuroscientific support, little research has examined its psychologic...
Objectives: To perform a Bayesian reanalysis of a recent trial of psilocybin (COMP360) versus escitalopram for Major Depressive Disorder (MDD) in order to provide a more informative interpretation of the indeterminate outcome of a previous frequentist analysis. Design: Reanalysis of a two-arm double-blind placebo controlled trial. Participants: Fifty-nine pa...
Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating a range of psychiatric disorders, including depression, addiction, eating disorders, post-traumatic stress disorder, and others. ‘Classic’ serotonergic psychedelics, such as psilocybin, lysergic acid diethylamide (LSD), N, N-Dimethyltryptamine (DMT) and 5-metho...
Background: The use of psychedelic compounds to treat psychiatric disorders has become a very significant topic of research over the past several years. Psilocybin has risen to prominence as one of the most studied among these psychedelic compounds. Multiple trials have already shown that it can be a safe and efficacious treatment for various medical conditi...
This document details an authors' response to a critique of their work entitled: Skepticism About Recent Evidence that Psilocybin Opens Depressed Minds.
Research on the therapeutic potential of psychedelic substances is rapidly expanding. A major limitation within this field is the unpredictability of individual responses to psychedelic substances. A better understanding of factors that can predict psychedelic experience is essential to both clinical progress and wider harm reduction frameworks. Ketamine, MD...
Psychedelic drugs such as psilocybin are under investigation for the treatment of several psychiatric conditions. They also have the remarkable property of producing persisting positive psychological changes in healthy volunteers for at least several months. In this study, 35 medium-high doses of psilocybin were administered to 28 healthy volunteers (12 fema...
Background: Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the validity of Carhart-Harris & Nutt (2017) model of extra-pharmacological (EP) factors and examined whether such factors should be taken into account in any psychological suitability test for medicinally pr...
Background and Aims: The benefits of classic serotonergic psychedelics (e.g. psilocybin, LSD, DMT, ayahuasca) are becoming more widely known with the resurgence in research in the past decade. Furthermore, the benefits of mindfulness are well documented. However, no systematic reviews have examined linkage of mindfulness and psychedelics use. The aim of this...
Treatments for addressing psychiatric mental health issues in vulnerable patients with cancer are established. Yet, many patients persist with unrelenting psychological difficulties despite intervention. There is growing interest in the role of psilocybin-assisted psychotherapy for managing treatment-resistant mental health challenges in patients with cancer...
In this précis I summarise the main ideas of my book Philosophy of Psychedelics. The book discusses philosophical issues arising from the therapeutic use of classic psychedelic drugs such as psilocybin and LSD. The book is organised around what I call the Comforting Delusion Objection to psychedelic therapy: the concern that this novel and promising treatmen...
"The Psilocybin for Depression: The ACE Manual '' describes the structure, procedures, and scripts used in the two Imperial College London studies (Psilodep) researching psilocybin treatment for major depression.
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to...
Introduction: Microdosing refers to the repetitive administration of tiny doses of psychedelics (LSD, Psilocybin) over an extended period of time. This practice has been linked to alleged cognitive benefits, such as improved mood and creativity, potentiated by targeting serotonergic 5-HT2A receptors and facilitating cognitive flexibility. Nonetheless, in the...
